AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial

Tarih
2007
Yazar
Huigol, Nagraj G.
Kizilbash, Noor-I-Alam
Kagiya, V. Tsutomu
Tatsuzaki, Hideo
Okkan, Sait
Dobrowsky, Werner
Jayatilake, Ranapala S.
Üst veri
Tüm öğe kaydını göster
Özet
Purpose: AK-2123, a nitrotriazole hypoxic cell sensitizer, has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage III and IV.
Bağlantı
http://hdl.handle.net/20.500.12627/33957
https://doi.org/10.1016/j.radonc.2006.11.007
Koleksiyonlar